UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

Cancer chemotherapy and pharmacology, 2013-06, Vol.71 (6), p.1395-1409

Britten, Carolyn D.

2013

Volltextzugriff (PDF)

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

The lancet oncology, 2018-01, Vol.19 (1), p.51-64

2018

Volltextzugriff (PDF)

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

Journal of hematology and oncology, 2017-04, Vol.10 (1), p.82-82, Article 82

2017

Volltextzugriff (PDF)

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib

Molecular cancer therapeutics, 2012-09, Vol.11 (9), p.1978-1987

2012

Volltextzugriff (PDF)

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3267-3279

2001

Volltextzugriff (PDF)

Targeting ErbB receptor signaling: A pan-ErbB approach to cancer

Molecular cancer therapeutics, 2004-10, Vol.3 (10), p.1335-1342

Britten, Carolyn D

2004

Volltextzugriff (PDF)

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

Cancer chemotherapy and pharmacology, 2008-03, Vol.61 (3), p.515-524

2008

Volltextzugriff (PDF)

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Journal of clinical oncology, 2017-07, Vol.35 (19), p.2117-2124

2017

Volltextzugriff (PDF)

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study

BMC cancer, 2012-01, Vol.12 (1), p.16-16, Article 16

2012

Volltextzugriff (PDF)

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

Clinical cancer research, 2015-02, Vol.21 (4), p.730-738

2015

Volltextzugriff (PDF)

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors

Clinical cancer research, 2017-08, Vol.23 (16), p.4642-4650

2017

Volltextzugriff (PDF)

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Investigational new drugs, 2020-06, Vol.38 (3), p.800-811

2020

Volltextzugriff (PDF)

Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy

Annual review of cancer biology, 2022-04, Vol.6 (1), p.17-34

2022

Volltextzugriff (PDF)

Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology

American journal of clinical oncology, 2022-08, Vol.45 (8), p.352-365

2022

Volltextzugriff (PDF)

Automatic trial eligibility surveillance based on unstructured clinical data

International journal of medical informatics (Shannon, Ireland), 2019-09, Vol.129, p.13-19

2019

Volltextzugriff (PDF)

Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor

Clinical cancer research, 2006-06, Vol.12 (11), p.3408-3415

2006

Volltextzugriff (PDF)

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

Clinical cancer research, 2011-03, Vol.17 (5), p.1131-1139

2011

Volltextzugriff (PDF)

A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies

Clinical cancer research, 2002-07, Vol.8 (7), p.2142-2148

2002

Volltextzugriff (PDF)

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer

Journal of cancer research and clinical oncology, 2014-03, Vol.140 (3), p.443-452

2014

Volltextzugriff (PDF)

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

Targeted oncology, 2017-12, Vol.12 (6), p.775-785

2017

Volltextzugriff (PDF)

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Cancer chemotherapy and pharmacology, 2018-08, Vol.82 (2), p.285-298

2018

Volltextzugriff (PDF)

Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients

American journal of roentgenology (1976), 2017-10, Vol.209 (4), p.722-732

2017

Volltextzugriff (PDF)

A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer

Investigational new drugs, 2021-12, Vol.39 (6), p.1613-1623

2021

Volltextzugriff (PDF)

Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344

The Journal of pharmacology and experimental therapeutics, 2016-08, Vol.358 (2), p.199-208

2016

Volltextzugriff (PDF)

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

Investigational new drugs, 2014-06, Vol.32 (3), p.510-517

2014

Volltextzugriff (PDF)

1 – 25 von 74

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(74)

Sprache

Englisch
(74)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(50)
Science & Technology
(50)
Humans
(47)
Oncology
(43)
Female
(36)
Aged
(32)
Middle Aged
(32)
Male
(31)
Adult
(26)
Neoplasms - Drug Therapy
(26)
Biological And Medical Sciences
(22)
Medical Sciences
(22)
Pharmacology. Drug Treatments
(22)
Antineoplastic Agents
(21)
Dose-Response Relationship, Drug
(17)
Pharmacology & Pharmacy
(16)
Medicine
(15)
Antineoplastic Agents - Adverse Effects
(14)
Antineoplastic Agents - Pharmacokinetics
(14)
Chemotherapy
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Targeting ErbB receptor signaling: A pan-ErbB approach to cancer

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors

Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma

Targeting Solid Tumors with Bispecific T Cell Engager Immune Therapy

Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology

Automatic trial eligibility surveillance based on unstructured clinical data

Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor

Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies

Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer

Comparison of Triple-Drug Transcatheter Arterial Chemoembolization (TACE) With Single-Drug TACE Using Doxorubicin-Eluting Beads: Long-Term Survival in 313 Patients

A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer

Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344

Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer

Suchergebnisse filtern